Efficacy News and Research

RSS

Aerovance starts phase IIb clinical trial with Aerovant for uncontrolled asthma

Aerovance Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial, of inhaled dry powder Aerovant in patients with uncontrolled asthma.

2 Apr 2009

Sorafenib may help patients suffering from advanced portal hypertension

In a new study, a therapeutic agent called sorafenib dramatically improved the condition of rats with portal hypertension.

1 Apr 2009

New understanding on how probiotics can prevent disease

Using probiotics successfully against a number of animal diseases has helped scientists from University College Cork, Ireland to understand some of the ways in which they work, which could lead to them using probiotics to prevent and even to treat human diseases.

1 Apr 2009

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

CeNeRx BioPharma, Inc. has announced issuance of a new U.S. patent covering its novel compounds that selectively target peripheral cannabinoid receptors.

1 Apr 2009

New HIV drug may help patients not responding to treatment

A potential treatment for HIV may one day help people who are not responding to Anti-Retroviral Therapy, suggests new research published tomorrow in The Journal of Immunology.

1 Apr 2009

New smoking cessation drug varenicline tartrate shows promise in trials

Research has shown that varenicline tartrate - a novel new drug specifically developed for smoking cessation - allows smokers to abstain from cigarettes significantly longer and more effectively than smokers using a placebo.

31 Mar 2009

Requirement for pediatric cardiac devices highlighted by off-label procedures

Nearly two-thirds of children who undergo routine interventional cardiology procedures -- those involving a catheter to treat structural disorders of the heart -- may be receiving treatment with a device that's being used for an off-label application.

30 Mar 2009

Discovery of 'lock-like' molecule may provide new ways to starve cancer tumors or prevent drug side effects

Scientists have shed new light -- literally -- on a possible way to starve cancer tumors or prevent side effects from a wide range of drugs.

30 Mar 2009

AHF lauds ‘Lancet’ editorial criticizing Pope on condoms and HIV

AIDS Healthcare Foundation (AHF) today lauded the respected British medical journal, 'The Lancet,' for its strongly-worded editorial criticizing Pope Benedict XVI for his public remarks early last week suggesting that condoms are fueling the spread of AIDS in Africa.

30 Mar 2009

NPR program examines efforts to improve BCG tuberculosis vaccine

NPR's "Morning Edition" last week examined the Aeras Global TB Vaccine Foundation's efforts to improve the existing BCG vaccine to provide increased protection against tuberculosis.

30 Mar 2009

Corthera's Relaxin in acute heart failure shows promising results

Corthera Inc. has announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, placebo-controlled international study, demonstrated promising efficacy and safety for relaxin, the company's investigational drug for treatment of acute heart failure (AHF).

30 Mar 2009

New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography

Lantheus Medical Imaging, Inc has announced new data regarding the use of DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension.

29 Mar 2009

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Data from a new study showed that Abbott's TRILIPIX (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints.

29 Mar 2009

ARCA biopharma presents data from phase 3 BEST trial of Gencaro

ARCA biopharma, Inc. has announced that data from the pivotal Phase 3 BEST trial of Gencaro (bucindolol hydrochloride) in patients with advanced chronic heart failure (CHF) was presented at the American College of Cardiology 58 th Annual Scientific Session being held March 29-31, 2009 in Orlando, Florida.

29 Mar 2009

Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes

Findings published in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor, produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)] in treatment-naive type 2 diabetes patients, compared to placebo.

29 Mar 2009